Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.67 |
| ▸ | TSHR | P16473 | 6/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090989 | 0.90 | HIF1A (0.76) | CYP3A4CYP1A2TSHRCYP2D6ALDH1A1 | |
| SCHEMBL4085263 | 0.89 | HIF1A (0.79) | CYP3A4CYP1A2TSHRALDH1A1HSD17B10 | |
| SCHEMBL1084026 | 0.88 | HIF1A (0.76) | CYP3A4CYP1A2TSHRCYP2D6ALDH1A1 | |
| SCHEMBL31612748 | 0.86 | MEN1 (0.74) | CYP3A4CYP1A2TSHRCYP2D6ALDH1A1 | |
| SCHEMBL5788913 | 0.86 | CYP1A2 (0.63) | CYP3A4CYP1A2TSHRCYP2D6ALDH1A1 | |
| SCHEMBL4091345 | 0.86 | CYP1A2 (0.66) | CYP3A4CYP1A2TSHRCYP2D6ALDH1A1 | |
| SCHEMBL5804844 | 0.86 | CYP1A2 (0.63) | CYP3A4CYP1A2TSHRCYP2D6ALDH1A1 | |
| SCHEMBL4089767 | 0.85 | GBA1 (0.60) | CYP3A4CYP1A2TSHRCYP2D6ALDH1A1 | |
| SCHEMBL1083917 | 0.83 | TSHR (0.74) | CYP3A4CYP1A2TSHRCYP2D6ALDH1A1 | |
| SCHEMBL4755906 | 0.82 | HIF1A (0.56) | CYP3A4CYP1A2TSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | CYP3A4 2113/4885CYP1A2 2477/4885TSHR 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.